Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Xylem, Inc. — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B), while Xylem, Inc. trades at $123.19 (market cap $28.30B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.7× Xylem, Inc.'s market cap, and Xylem, Inc. pays a 1.42% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | XYL | |
|---|---|---|
Market Cap | $132.79B | $28.30B |
Sector | Health | Industrials |
52-Week High | $529.65 | $152.95 |
52-Week Low | $376.62 | $106.34 |
Enterprise Value | $126.92B | $30.08B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Xylem (XYL) trades at $120.32, down 0.36% on the day, with a neutral technical signal and key support at $120. The company reported strong Q2 2026 earnings of $1.46 per share, beating estimates, and raised its full-year profit guidance. Revenue growth has been steady, reaching $9.04B in 2025, with net income margins improving to 10.59%. Analyst sentiment is mixed, with a consensus price target of $150.43, implying significant upside from current levels.
The outlook for XYL is positive, driven by robust demand in water technology and AI infrastructure, alongside margin expansion. Key risks include project delays in electric metering and competitive pressures. With a P/E of 28.65, the stock trades at a premium, but continued execution on earnings and strategic acquisitions supports a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
